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Introduction: Kidney fibrosis has shown to be ameliorated through the involvement
of cyclic guanosine monophosphate (cGMP) and its dependent protein kinase I (cGKI).
Serelaxin, the recombinant form of human relaxin-II, increases cGMP levels and has
shown beneficial effects on kidney function in acute heart failure patients. Antifibrotic
properties of serelaxin are supposed to be mediated via relaxin family peptide receptor
1 and subsequently enhanced nitric oxide/ cGMP to inhibit transforming growth factor-
β (TGF-β) signaling. This study examines the involvement of cGKI in the antifibrotic
signaling of serelaxin.
Methods and Results: Kidney fibrosis was induced by unilateral ureteral obstruction in
wildtype (WT) and cGKI knock-out (KO) mice. After 7 days, renal antifibrotic effects
of serelaxin were assessed. Serelaxin treatment for 7 days significantly increased
cGMP in the kidney of WT and cGKI-KO. In WT, renal fibrosis was reduced through
decreased accumulation of collagen1A1, total collagen, and fibronectin. The profibrotic
connective tissue growth factor as well as myofibroblast differentiation were reduced and
matrix metalloproteinases-2 and -9 were positively modulated after treatment. Moreover,
Smad2 as well as extracellular signal-regulated kinase 1 (ERK1) phosphorylation were
decreased, whereas phosphodiesterase (PDE) 5a phosphorylation was increased.
However, these effects were not observed in cGKI-KO.
Conclusion: Antifibrotic renal effects of serelaxin are mediated via cGMP/cGKI to inhibit
Smad2- and ERK1-dependent TGF-β signaling and increased PDE5a phosphorylation.
Keywords: Relaxin, serelaxin, cGMP-dependent protein kinase, kidney, interstitial fibrosis, signaling, nitric oxide
Abbreviations: α-SMA, α-smooth muscle actin; cGKI, cGMP-dependent protein kinase 1; cGMP, cyclic guanosine
monophosphate; CKD, chronic kidney disease; Col1A1, collagen1A1; CTGF, connective tissue growth factor; ECM,
extracellular matrix; eNOS, endothelial nitric oxide synthase; ERK, extracellular-signal regulated kinase; GAPDH,
glyceraldehyde-3-phosphate dehydrogenase; KO, knock out; MMP, matrix metalloproteinase; NO, nitric oxide; PDE,
phosphodiesterase; P-VASP, phospho-vasodilator-stimulating phosphoprotein; RLX, serelaxin; RXFP1, relaxin family
peptide receptor 1; Smad, small mothers against decapentaplegic protein; TGF-β, transforming growth factor-β; UUO,
unilateral ureteral obstruction; WT, wildtype.
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INTRODUCTION
Kidney fibrosis is a key contributor to CKD, mainly resulting
from diabetes or hypertension in developed countries.
The prevalence of CKD is estimated 7.2% in patients
aged 30 years or older (Zhang and Rothenbacher, 2008).
Renal fibrosis is characterized by excessive accumulation
of ECM including collagen and fibronectin. TGF-β and
CTGF are profibrotic cytokines which promote fibroblast to
myofibroblast differentiation expressing α-smooth muscle
actin (α-SMA). These cells are predominantly expressed in
fibrotic tissue contributing to the deposition of ECM and
modulation of MMPs. To prevent or reduce renal fibrotic
tissue, the modulation of cyclic nucleotides, particularly
cGMP might be promising. cGMP has already shown to be
increased in kidney fibrosis as well as further increased through
pharmacological intervention for the amelioration of kidney
fibrosis and improvement of renal function (Wang et al., 2006).
Currently, cGMP modulation is achieved by several therapeutic
approaches including NO donors and soluble guanylate cyclase
(sGC) stimulators (Schlossmann and Schinner, 2012).
Relaxin was firstly described by Hisaw (1929) due to
its antifibrotic effects in the reproductive system. By now,
RLX showed pleiotropic effects in several experimental and
clinical research, mainly mediated through its G-protein coupled
receptor RXFP1 (Bathgate et al., 2013). Antifibrotic effects
involve NO, sGC and the downstream mediator cGMP to inhibit
TGF-β signaling (Samuel, 2005; Halls et al., 2015; Wang et al.,
2016). RLX – the recombinant form of the naturally occurring
human pregnancy hormone relaxin-II – is a cGMP modulating
agent, which is currently being tested in a phase III clinical
trial for acute heart failure. About 18% to 40% of patients with
acute heart failure also experience worsening of renal function
during acute decompensation, which adversely affects prognosis
(Cole et al., 2012). Serelaxin has already shown improved organ
function as indicated by reduced biomarker levels for renal
damage after recompensation (Metra et al., 2013; Teerlink et al.,
2013).
Schinner et al. (2013) and Cui et al. (2014) have demonstrated
renal antifibrotic signaling via NO/cGMP and the cGMP-
dependent protein kinase I (cGKI) in rodents after the
administration of NO donors and soluble guanylyl cyclase
stimulators. However, a possible role of cGKI in RLX’s antifibrotic
effect still remains unclear.
Further research is necessary to elucidate downstream
mechanisms involved in the RXFP1- NO/cGMP-dependent
antifibrotic pathway. The aim of this study was to examine
the antifibrotic-signaling pathway of RLX in the kidney. We
hypothesized that RLX’s antifibrotic properties are mediated
through cGKI.
MATERIALS AND METHODS
Animals
129/Sv-WT and 129/Sv-cGKI-KO mice (Pfeifer et al., 1998) were
bred and maintained in the animal facilities of University of
Regensburg. Experiments are conducted according to the guide
for the Care and Use of Laboratory Animals published by the
US National Institute of Health. Protocols were approved by
local authorities for animal research (Regierung der Oberpfalz,
Bayern, Germany, #54-2532.1-26/13) and conducted according
to German law for animal care.
UUO and RLX Treatment
Unilateral ureteral obstruction, an established mouse model for
chronic renal interstitial fibrosis (Chevalier et al., 2009), was
performed according to Schinner et al. (2013) Kidney tissues
of WT and cGKI-KO mice were divided into four groups:
mice untreated or treated with RLX. Fibrotic tissue was derived
from UUO-obstructed kidney, healthy tissue from contralateral
kidney served as control. RLX was diluted in 20 mM sodium
acetate (pH= 5) and administered continuously through osmotic
minipumps (Alzet; model 1007D) immediately after UUO for
7 days (0.5 mg/kg/day).
Tissue Preparation
Under isoflurane inhalation kidney tissue was removed
after perfusion with 0.9% NaCl 7 days after UUO.
Proteins from kidney tissue were solubilized in 50 mM
Tris/2% SDS/phosphatase inhibitor (PhosSTOP, Roche; 1
tablet/5 ml)/protease inhibitors (leupeptin 0.5 µg/ml, PMSF
300 µM, benzamidine hydrochlorid 1 mM, and EDTA 5 mM) for
45 min at 7◦C followed by centrifugation at 12400g, 7◦C, 45 min.
In supernatants, protein content was determined by modified
Lowry method (Lowry et al., 1951) and stored at −80◦C until
analysis.
Western Blot Analysis
Protein expression of GAPDH, ERK1/2, P- ERK1/2, P-Smad2,
P-VASP (Ser 239), GAPDH (antibodies from Cell Signaling,
Danvers, MA, USA), TGF-β, CTGF, PDE5a (antibodies from
Santa Cruz Biotechnology, Heidelberg, Germany) and P-PDE5a
(Ser 92) (FabGennix, Frisco, TX, USA) were assayed by
western blotting. After SDS-PAGE proteins were transferred
to PVDF membranes. Donkey anti-goat IgG HRP (santa
cruz Biotechnology, Heidelberg, Germany) and donkey anti-
rabbit IgG HRP (Dianova GmbH, Hamburg, Germany) were
used as secondary antibodies. Quantification was performed
by ImageLabTM densitometry software (BioRad, München,
Germany). Values were related to corresponding GAPDH values,
except P-ERK1/2 is related to ERK1/2. Change of markers from
healthy to fibrotic tissue was compared by values of fibrotic
tissue in relation to healthy tissue, both untreated WT mice.
The influence of treatment on markers was determined only in
fibrotic tissue by analyzing values of markers in relation to mean
values of untreated fibrotic WT, which were set as 1.
Gelatin Zymography Assay
The activity of MMP2 and MMP9 was determined using gelatin
zymography. SDS-PAGE was performed with a gel containing
0.1% gelatin. After washing (100 mM NaCl and 2.5% Triton X-
100 in 50 mM Tris-HCl, pH 7.5) the gel was transferred to a
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reaction buffer (200 mM NaCl, 0.02% NaN3, 0.5 µM ZnCl2,
1 mM CaCl2, 2% Triton-X 100, in 50 mM Tris-HCl, and pH
7.5) for enzymatic reaction at 37◦C overnight. Gel was stained
with Coomassie blue, destained in 10% acetic acid (v/v), and 30%
methanol (v/v) and quantified using Image Lab. MMPs in fibrotic
tissue were expressed as relative values of markers in fibrotic
kidneys from untreated WT mice.
Enzyme-Linked Immunosorbent Assays
Serelaxin serum levels were determined using Human Relaxin-
2 Quantikine R© ELISA (R&D Systems, Wiesbaden-Nordenstadt,
Germany). cGMP levels in kidney tissue using cGMP EIA (IBL-
Cayman, Hamburg, Germany). Measurements were performed
according to manufacturer’s instructions.
Sirius Red/Fast Green Method for
Quantification of Collagen
Collagen levels in the kidneys were measured by a modified sirius
red/fast green method (Lopez-De Leon and Rojkind, 1985), based
on selective binding of sirius red to collagen and fast green dye
binding to non-collagen proteins. Sirius red/fast green staining
was calculated as increase (%) of collagen [ratio collagen/non-
protein collagen] after 7 days UUO related to healthy kidney as
described previously (Schinner et al., 2013).
Immunohistochemistry
Kidney tissues were cut at 4 µm. Immunohistochemistry and
quantification was performed according to Schinner et al.
(2013) Primary antibodies are mouse anti-α-SMA (Beckman
Coulter, Krefeld, Germany), rabbit anti-Col1a1 and rabbit anti-
fibronectin (Abcam, Cambridge, UK). Alexa 647-conjugated
donkey anti-rabbit and Cy2-conjugated donkey anti-mouse
served as secondary antibodies. For quantification the increase
after UUO was related to the healthy kidney.
Quantitative RT-PCR
Isolation of total RNAs from kidney tissue, determination
using quantitative RT-PCR as well as calculation was described
previously (Schinner et al., 2013). mRNA levels of αSMA,
fibronectin, Col1a1, MMP2, and MMP9 were detected. 18S rRNA
served as housekeeping gene. The 11CT (cycle threshold) value
is calculated from the difference of the corresponding control (C)
and fibrosis-induced kidneys (F) [11CT =1CT(C)−1CT(F)].
Then, the ratio of expression (r) was determined [r = 211CT].
Serum Creatinine
Serum creatinine was determined by a previously published
HPLC method with minor modifications (Schramm et al., 2014).
Serum (10 µl) was mixed with 50 µl perchloric acid to precipitate
proteins. The tube was mixed, kept at 4◦C for 15 min, then
centrifuged (5 min, 10,800 g). 5 µl of the supernatant was injected
into the HPLC apparatus (Prominence LC20 series equipped
with a LC20A photometric detector set at 234 nm; Shimadzu,
Duisburg, Germany). Separation was performed using a Zorbax
300-SCX 5 µm, 150 × 4.6 mm, analytical column (Agilent,
Waldbronn, Germany) and a mobile phase consisting of 5 mM
sodium acetate (pH = 5.1)/acetonitrile (800:200, v:v). Creatinine
eluted after 6.3–6.5 min at a flow rate of 1.0 ml/ min (column
temperature 35◦C).
Statistical Analysis
All data are expressed as mean ± SEM. Statistical differences
between two means were calculated by unpaired student’s t-test
(two-tailed, confidence interval 95%). Statistical significance was
marked by asterisks (∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001). n
indicates number of animals. For data analysis, GraphPad Prism,
version 6 (GraphPad software, Inc., La Jolla, CA, USA), was used.
RESULTS
Effect of RLX on cGMP and cGKI in
Kidney Tissue
Plasma levels of relaxin were determined through RLX ELISA in
WT and cGKI-KO mice. In untreated mice serum levels were
at 11.4 ± 1.4 pg/ml for WT (n = 11) and at 0.04 ± 0.04 pg/ml
for cGKI-KO (n = 5). In RLX-treated mice serum levels
increased to 20361 ± 2290 pg/ml for WT (n = 14) and
13357 ± 3122 pg/ml for cGKI-KO mice (n = 4, not significantly
different for WT and cGKI-KO), which was highly statistically
significant compared to untreated mice (WT: p < 0.001; cGKI-
KO: p= 0.0018).
cGMP levels were investigated in kidney tissue. Figure 1A
shows that cGMP was higher in fibrotic tissue 7 days after UUO
than in the contralateral kidney (42.8± 5.7 vs. 25.9± 5.2 pmol/g).
After RLX treatment cGMP levels of fibrotic kidneys further
increased significantly (95.0± 12.5 pmol/g).
The activity of cGKI can be determined by quantification of
cGKI-specific VASP phosphorylation at Serine 239. In Figure 1B
an increase of VASP phosphorylation was observed after RLX
treatment, in healthy and in fibrotic WT tissues. The increase
in WT mice, expressed as relative values in kidneys from
untreated WT mice, changed from 0.94 ± 0.12 (n = 5)
to 1.68 ± 0.32 (n = 5) after treatment. In cGKI-KO this
effect was lacking (0.79 ± 0.22; n = 3 vs. 0.86 ± 0.17;
n= 2).
Effect of RLX on α-SMA in WT- and
cGKI-KO Kidneys
mRNA of α-SMA, a marker of myofibroblast differentiation,
(Nagamoto et al., 2000) was increased in both WT and cGKI-KO
after UUO. A reduction of mRNA was observed after treatment
with RLX in WT, whereas no effect was seen in cGKI-KO
after treatment (Figure 2A). As expected, in unobstructed renal
tissue only vascular smooth muscle cells were immunostained
with α-SMA, in UUO-obstructed kidneys enhanced interstitial
expression was observed (data not shown). In WT, α-SMA
protein was elevated compared to the contralateral kidney,
after RLX treatment the increase was significantly reduced. In
cGKI-KO no significant reduction of α-SMA protein expression
through RLX was demonstrated (Figure 2B).
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FIGURE 1 | Determination of (A) cGMP levels and (B) protein kinase activity of cGKI, determined by VASP phosphorylation (Ser239) in healthy or
fibrotic kidney tissue of WT mice 7 days after UUO; mice were untreated or treated with serelaxin for 7 days during UUO. As described in methods
increase of renal cGMP levels was quantified with ELISA according to manufacturer’s instructions. VASP phosphorylation at Ser 239 was determined by western
blotting (50 µg protein) after normalization to GAPDH; cGMP, cyclic guanosine monophosphate; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; P-VASP,
phospho-vasodilator- stimulating phosphoprotein; RLX, serelaxin; UUO, unilateral ureteral obstruction; ∗∗∗p < 0.001.
FIGURE 2 | Effect of serelaxin on (A) mRNA and (B) protein expression of α-SMA in kidney tissue of WT and cGKI-KO mice. mRNA was determined with
RT-qPCR and 18s rRNA as housekeeping gene. Results are shown as fold change of mRNA expression (211ct) in the fibrotic kidney relative to contralateral
healthy kidney, which was set as 1. The increase of α-SMA protein expression [%] in fibrotic renal tissue compared to contralateral kidney was quantified by
immunohistochemistry; α-SMA, α-smooth muscle actin; cGKI, cGMP-dependent protein kinase I; KO, knockout; RLX, serelaxin; UUO, unilateral ureteral obstruction;
WT, wildtype, ∗p < 0.05.
Effect of RLX on ECM Accumulation in
WT- and cGKI-KO Kidneys
Fibronectin and Col1A1 are components of ECM, whose
gene expressions are upregulated in fibrosis through
TGF-β signaling. mRNA of both genes were elevated in
fibrotic WT kidney 7 days after UUO compared to the
contralateral kidney. Fibronectin and Col1A1 mRNA
were reduced through RLX in WT (Figures 3B and 4A).
Protein expression was strongly elevated by more than 40%
for fibronectin and Col1A1 in both WT and cGKI-KO
mice, compared to kidneys without UUO (for fibronectin,
Figures 3A,C). Significant reduction of both proteins through
RLX treatment was observed only in WT after 7 days of
treatments.
Protein expression of total collagen was elevated by
21.4% ± 0.99 in fibrotic WT and significantly decreased
through RLX treatment to an elevation of 16.6%± 1.7 compared
to unobstructed kidneys (p = 0.0126). In cGKI-KO, effects of
RLX on ECM accumulation were not observed (Figures 3A,C
and 4B,C).
Regulation of MMPs by RLX in WT- and
cGKI-KO Kidneys
MMPs are relevant for the degradation of ECM. mRNA of
MMP2 was 6.8-fold (± 0.58) increased in fibrotic tissue, whereas
MMP9 was not increased in that pathological condition (0.88-
fold ± 0.53). Through RLX treatment, only the elevated levels
of MMP2 mRNA were significantly decreased (4.3-fold ± 0.61),
no changes were found for MMP9 mRNA after treatment
(0.76-fold ± 0.067; Figures 5C,E). Zymography distinguishes
between latent and active MMP proteins (Figures 5A,B). In
WT, latent and active forms of MMP2 were elevated in
fibrosis (5.9-fold ± 1.3; 4.2-fold ± 0.84), protein expression
of latent MMP9 was significantly enhanced in fibrotic tissue
(3.0-fold ± 0.42), active form significantly decreased (0.69-
fold ± 0.098) compared to contralateral kidneys (n = 12,
respectively).
Figures 5D,F show regulation of MMPs only in fibrotic
tissue expressed as relative values of markers in kidneys from
untreated WT mice. Consistent with data from mRNA, latent
and active forms of MMP2 were both significantly reduced
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FIGURE 3 | (A) Immunohistochemical staining of fibronectin in kidney tissue of WT and cGKI-KO mice – healthy or 7 days after UUO treated or untreated with
serelaxin; effect of serelaxin on (B) mRNA and (C) protein expression of fibronectin in kidney tissue of WT and cGKI-KO mice; mRNA was determined with RT-qPCR
and 18s rRNA as housekeeping gene. Results are shown as fold change of mRNA expression (211ct) in the fibrotic kidney relative to contralateral healthy kidney,
which was set as 1. The increase of fibronectin protein expression [%] in fibrotic renal tissue compared to contralateral kidney was quantified by
immunohistochemistry; cGKI, cGMP-dependent protein kinase I; KO, knock out; RLX, serelaxin; UUO, unilateral ureteral obstruction; WT, wildtype. ∗∗p < 0.01.
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FIGURE 4 | Effect of serelaxin on (A) mRNA and (B) protein expression of Col1A1 as well as (C) protein expression of total collagen in kidney tissue of
WT and cGKI-KO mice. mRNA was determined with RT-qPCR and 18s rRNA as housekeeping gene. Results are shown as fold change of mRNA expression
(211ct) in the fibrotic kidney relative to contralateral healthy kidney, which was set as 1. The increase of Col1A1 protein expression [%] in fibrotic renal tissue
compared to contralateral kidney was quantified by immunohistochemistry; the increase of total collagen [%] was quantified with sirius red/fast green method; cGKI,
cGMP-dependent protein kinase I; Col1A1, collagen1A1; KO, knock out; RLX, serelaxin; UUO, unilateral ureteral obstruction; WT, wildtype. ∗p < 0.05, ∗∗p < 0.01.
through RLX treatment in fibrotic kidneys. Through reduction
of latent MMP9 and increase of active MMP9 after treatment
physiological conditions were nearly restored.
The above described effects on MMP2 and MMP9 were not
observed in cGKI-KO mice after treatment (Figures 5D,F).
Signaling Molecules in WT- and cGKI-KO
Kidneys Treated with RLX
As mentioned above, cGMP levels were elevated through RLX
and, so far, cGKI-KO mice showed no antifibrotic effects,
which suggested the involvement of the NO/cGMP/cGKI
pathway in the antifibrotic effect of RLX. Subsequently, several
signaling molecules were analyzed by western blotting, which are
involved in fibrosis. Representative western blots demonstrated
modulation of the selected markers in fibrotic conditions
compared to healthy (Figure 6A).
Downstream to RLX, protein expression of phosphorylated
ERK 1/2 (P-ERK1, P-ERK2) was analyzed. P-ERK1 was
significantly elevated in kidneys of WT mice compared to the
contralateral after undergoing UUO for 7 days (P-ERK1:1.8-
fold ± 0.24; n = 7). cGMP is degraded by PDE5a, which
is strongly upregulated in fibrosis (6.0-fold ± 1.3; n = 10),
whereas phosphorylation of PDE5a at the cGMP-dependent
phosphorylation site serine 92 (Thomas et al., 1990; 0.68-
fold± 0.12; n= 7) was decreased. TGF-β is a profibrotic cytokine,
that was 5.3-fold (± 1.1; n = 12) elevated in the fibrotic kidneys
compared to the contralateral renal WT tissue. Its downstream
profibrotic signaling is dependent on Smad or -independent via
ERK1/2 phosphorylation. Both P-Smad2 (1.926± 0.2384; n= 12)
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FIGURE 5 | Effect of serelaxin on (C), (E) mRNA and (A), (B), (D), (F) protein expression of MMP-2, MMP-9 determined by zymography (each 70 µg
protein) in kidneys from WT and cGKI-KO mice. (A) Representative blot from untreated WT, which illustrates active and latent MMP expression in healthy and
fibrotic renal tissue; (B) representative blot from fibrotic WT kidneys untreated or treated with serelaxin; mRNA was determined with RT-qPCR and 18s rRNA as
housekeeping gene. Results are shown as fold change of mRNA expression (211ct) in the fibrotic kidney relative to contralateral kidney, which was set as 1 [(C)
MMP2; (E) MMP9]; latent and active MMP expression determined by zymography (70 µg protein) and is shown only in fibrotic tissue. Each value of WT and
cGKI-KO is related to untreated fibrotic WT, which was set as 1 [(D) MMP2; (F) MMP9]; cGKI, cGMP-dependent protein kinase I; KO, knock out; MMP, matrix
metalloproteinase; RLX, serelaxin; UUO, unilateral ureteral obstruction gibt es nicht; WT, wildtype, ∗p < 0.05, ∗∗∗p < 0.001.
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FIGURE 6 | (A) Representative western blots (each 50 t¸g protein) of signaling molecules in kidney tissue of WT mice with or without UUO untreated or treated with
serelaxin; (B) effect of serelaxin on protein expression of signaling molecules (P-ERK2/ERK2, P-ERK1/ERK1, PDE5a, P-PDE5a, TGF-β, CTGF, P-SMAD2) in fibrotic
kidney from WT and cGKI-KO mice; in Figure 5 (B) effects of serelaxin on protein expression of markers (normalized to GAPDH) was determined only in fibrotic
tissue. Each value of WT and cGKI-KO is related to untreated fibrotic WT, which was set as 1; α-SMA, α-smooth muscle actin; cGKI, cGMP-dependent protein
kinase I; cGMP, cyclic guanosine monophosphate; CTGF, connective tissue growth factor; ECM, extracellular matrix; eNOS, endothelial nitric oxide synthase; ERK,
extracellular-signal regulated kinase; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; GMP, guanosine monophosphate; KO, knock out; MMPs, matrix
metalloproteinases; PDE5a, phosphodiesterase 5a; RLX, serelaxin; RXFP1, relaxin receptor; Smad, small mothers against decapentaplegic protein; TGF-β,
transforming growth factor-β; UUO, unilateral ureteral obstruction; WT, wildtype, ∗p < 0.05, ∗∗p < 0.01.
Frontiers in Pharmacology | www.frontiersin.org 8 July 2016 | Volume 7 | Article 195
fphar-07-00195 July 9, 2016 Time: 13:1 # 9
Wetzl et al. cGMP-Dependent Antifibrotic Signaling of Serelaxin
and ERK-1 (see above) were significantly elevated in fibrotic renal
WT tissue. Additionally, further TGF-β transcription genes, e.g.,
CTGF were analyzed in this experiment. It was confirmed, that
CTGF levels were elevated 3.3-fold (± 0.77; n= 12) in obstructed
WT kidneys.
Protein levels of all signaling markers were significantly
different in healthy and fibrotic kidney tissue from WT mice –
P-PDE5a was reduced, remaining markers increased in fibrosis.
Figure 6B illustrates the influence of RLX on markers only
in fibrotic tissue of WT and cGKI-KO. Values are related to
untreated fibrotic WT kidneys, which were set as 1.
The phosphorylation of ERK1 normalized to total ERK1 was
significantly reduced in WT through RLX treatment, but not in
cGKI-KO.
eNOS and nNOS were increased in fibrosis, but were not
further enhanced after treatment with RLX (data not shown).
The cGMP degrading PDE 5a is slightly enhanced through
RLX in WT, and furthermore RLX significantly enhanced
phosphorylation of PDE5a, indicating enhanced activity of
PDE5a in fibrosis. The treatment-dependent increase in PDE5a
phosphorylation is lacking in cGKI-KO. TGF-β itself remained
unchanged in fibrotic tissue despite RLX treatment, but
downstream signaling of TGF-β was affected through treatment.
RLX significantly reduced P-Smad2 in WT, but not in cGKI-
KO. Signaling via Smad-independent pathway was regulated
through ERK1/2 phosphorylation (Leask and Abraham, 2004).
As mentioned above, ERK1 phosphorylation was significantly
reduced after treatment only in WT kidneys.
As previously stated, collagen, fibronectin and myofibroblast
differentiation (α-SMA) was decreased (see above). 7 days after
UUO continuous infusion of RLX decreased CTGF significantly
in WT, but not in cGKI-KO.
Effect of RLX on Kidney Function of WT-
and cGKI-KO Mice
Kidney function was measured by serum creatinine levels
analyzed 7 days after UUO. Figure 7 shows that serum
creatinine increased significantly after UUO, but renal
performance improved significantly through RLX treatment
by reducing serum creatinine levels from 1.0 mg/l ± 0.049 to
0.80 mg/l ± 0.069 in WT. cGKI-KO did not improve kidney
function through RLX.
DISCUSSION
In this study, we demonstrated that RLX mediated its antifibrotic
effects via NO/cGMP/cGKI, to inhibit TGF-β signaling through
Smad- and ERK1-dependent pathways (Figure 8).
Serelaxin modulated remodeling processes on several levels
resulting in reduced ECM accumulation. Samuel et al. (2003)
demonstrated that relaxin-1 deficient mice developed age-related
fibrosis in the kidney and other organs. Endogenous relaxin
was able to reduce early fibrotic changes in kidney tissue
after UUO (Hewitson et al., 2007). RLX administration has
already shown renal antifibrotic effects in models of kidney
injury, including renal papillary necrosis (Garber et al., 2001),
FIGURE 7 | Serum creatinine levels in healthy mice or 7 days after UUO
in WT and cGKI-KO mice. Serum creatinine levels were determined via high
pressure liquid chromatography as described in methods. cGKI,
cGMP-dependent protein kinase I; KO, knock out; RLX, serelaxin; WT,
wildtype, ∗p < 0.05.
FIGURE 8 | Proposed hypothesis for in vivo antifibrotic signaling
pathway of serelaxin in kidney. Serelaxin mediates its antifibrotic effect via
RXFP1/cGMP/cGKI to inhibit TGF-β dependent Smad- and
ERK-phosphorylation, which subsequently decreases ECM accumulation and
suppresses profibrotic stimuli; α-SMA, α-smooth muscle actin; cGKI,
cGMP-dependent protein kinase I; cGMP, cyclic guanosine monophosphate;
CTGF, connective tissue growth factor; ECM, extracellular matrix; ERK,
extracellular-signal regulated kinase; GMP, guanosine monophosphate;
MMPs, matrix metalloproteinases; PDE5a, phosphodiesterase 5a; RXFP1,
relaxin family peptide receptor 1; Smad, small mothers against
decapentaplegic protein; TGF-β, transforming growth factor-β.
antiglomerular basement membrane model (McDonald et al.,
2003), spontaneously hypertensive rats (Lekgabe et al., 2005),
models of renal mass reduction (Garber et al., 2003), and UUO
(Hewitson et al., 2010).
In our study, renal interstitial fibrosis was induced by UUO
for 7 days, a method for rapid development of interstitial
fibrosis with enhanced ECM deposition (Chevalier et al., 2009)
In our experiments, ECM components and ECM-producing cells
were increased. Signaling pathways were regulated differently
in the fibrotic and unobstructed kidney tissue. TGF-β and
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CTGF, important profibrotic cytokines, were markedly elevated
in fibrotic kidneys. TGF-β signaling is mediated via Smad-
dependent or independent pathways to induce myofibroblast
differentiation and gene expression of collagens, fibronectin,
CTGF, ECM-degrading MMPs, and several other profibrotic
stimuli (Leask and Abraham, 2004). In accordance with previous
work on UUO (Masaki et al., 2003; Pat et al., 2005; Hewitson et al.,
2010), in the current experiment both signaling mechanisms are
activated in fibrotic tissues, indicated through enhanced ERK1 as
well as Smad2 phosphorylation.
Animals were treated with RLX starting immediately after
UUO. cGMP was upregulated in fibrotic tissue and further
increased in mice treated with RLX, suspecting a cGMP-
dependent-signaling mechanism for RLX. The NO/cGMP-
signaling pathway has often been demonstrated to influence
remodeling processes in different organs, including the kidney
(Wang-Rosenke et al., 2011; Sun et al., 2012; Schinner et al.,
2015). PDE inhibitors have already shown their antifibrotic
effects by enhanced cGMP availability (Rodriguez-Iturbe et al.,
2005; Bae et al., 2012). cGKI is involved in the signaling process
of RLX, as RLX treated WT mice caused enhanced activity of
cGKI, indicated by the cGKI-specific phosphorylation at Ser239
of VASP and Ser92 of PDE5 compared to untreated mice. The
association of cGKI with antifibrotic effects was already shown
by Schinner et al. (2013) and Cui et al. (2014 in a model of
UUO-induced renal fibrosis. This was confirmed in our model
for RLX signaling, as we observed a significant antifibrotic and
antiremodelling effect indicated by reduced fibronectin, Col1A1,
total collagen and α-SMA in WT. These effects were lacking
in the cGKI-KO, suggesting an involvement of cGKI in the
antifibrotic properties of RLX in the kidney. As previously
observed (Schinner et al., 2013), fibrosis marker were reduced
in non-treated cGKI-KO compared to non-treated WT; however,
RLX treatment did not decrease fibrosis marker in cGKI-KO.
Serelaxin mainly realizes its antifibrotic effects via the relaxin
receptor RXFP1, which is present or expressed in the kidney (Hsu
et al., 2002; Halls et al., 2015) as well as in rat renal fibroblasts
and myofibroblasts in vitro (Masterson et al., 2004) and in vivo
(Mookerjee et al., 2009). The effect of RXFP1 on the enhancement
of NO still remains unclear. It is discussed, that it signals through
nNOS to enhance NO/cGMP in myofibroblasts (Mookerjee et al.,
2009; Chow et al., 2012) without the involvement of eNOS.
eNOS appears to have a more significant role in the arterial
vasodilatory effect (McGuane et al., 2011) of RLX than in the
antifibrotic. However, eNOS as well as nNOS were not increased
in our experiment, this does not exclude a role of eNOS or
nNOS in the protective effect of RLX as the interplay of the
diverse NOS isoforms in the suppression against interstitial
renal fibrosis was previously observed (Morisada et al., 2010).
Changes in the expression levels do not reveal the alterations
in the activity of these enzymes, e.g., an altered intracellular
calcium concentration would change the activity of the calcium-
dependent eNOS and nNOS. The inhibition of PDEs, e.g., the
cGMP specific PDE5a, also augments cGMP. However, PDE5a
was strongly enhanced in fibrosis, the phosphorylation of PDE5a
at the cGKI-specific phosphorylation site serine 92 (Thomas et al.,
1990) was additionally strongly upregulated after treatment. The
phosphorylation implicates increased enzyme activity as well as
augmented affinity of cGMP to allosteric-binding sites (Rybalkin
et al., 2002; Francis et al., 2010) suggesting an autoregulatory
feedback mechanism. Due to the cGKI-specific phosphorylation,
no effect of RLX on PDE5a phosphorylation was observed in
cGKI-KO.
There is evidence, that TGF-β protein levels are reduced
in vivo through RLX treatment (Garber et al., 2001). But
consistent with published data from Hewitson et al. (2010), we
confirmed that RLX has no influence on TGF-β1 protein levels in
kidney tissue in vivo. Most important TGF-β effects are regulated
through phosphorylation of Smad proteins (Massague, 1998) or
enhanced ERK1/2 signaling (Inoki et al., 2000). Suzuki et al.
(2004) as well as Piek et al. (2001) have shown, that fibronectin
synthesis is regulated via the TGF-β-dependent ERK1/2-signaling
pathway. Consistent with previous publications (Mookerjee
et al., 2009; Chow et al., 2014; Wang et al., 2016) we found
reduced Smad2 phosphorylation through RLX treatment to
abrogate ECM accumulation and myofibroblast differentiation.
TGF-β-dependent ERK signaling was also inhibited by reduced
phosphorylation of ERK1. As no effects of reduced Smad2
or ERK1 phosphorylation were observed in the cGKI-KO, we
suspect the involvement of cGKI in the suppression of TGF-β
signaling through RLX. The inhibition of ERK1 phosphorylation
through cGMP is in accordance to previous reports (Yeh
et al., 2010; Beyer et al., 2015). However, in cultured rat
renal myofibroblasts ERK1/2 phosphorylation was enhanced
(Mookerjee et al., 2009; Chow et al., 2012) and, in contrary, in
human renal fibroblasts no influence on ERK1/2 phosphorylation
was observed via RLX treatment (Heeg et al., 2005). Species and
cell-specific changes may explain different regulations.
The gelatinases MMP2 and MMP9 are ECM-degrading
enzymes involved in the remodeling processes of the kidney,
but their role is very complex. They are differently regulated in
published work (Heeg et al., 2005; Hewitson et al., 2007, 2010;
Chow et al., 2012). Upregulation increases the degradation of
ECM, but on the other hand they also activate TGF-β (Abreu
et al., 2002) and increase the degradation of collagen IV, which
is mainly included in the basement membrane and, therefore,
favors EMT (Ronco et al., 2007).
Matrix metalloproteinase 2 was strongly upregulated
in fibrotic kidney, whereas MMP9 was unchanged in this
pathological condition. Consistent with the current work,
in rodents after UUO elevated MMP2 levels (Sharma et al.,
1995) and decreased MMP9 activity (Gonzalez-Avila et al.,
1998) were found. MMP2 gene expression was shown to be
increased through Smad2-dependent TGF-β signaling (Piek
et al., 2001). Through RLX treatment both latent and active
MMP2 were decreased, which might be explained through
reduced phosphorylation of Smad2. The activity of MMP9 was
increased. Hewitson et al. (2010) showed similar results 9 days
after UUO, where MMP2 correlated with disease severity. The
regulation of MMP2 and MMP9 is assumed to be dependent
on cGKI, as cGKI-KO mice had no treatment-dependent MMP
regulation.
Connective tissue growth factor is an early downstream gene
of TGF-β, which augments fibrotic effects by directly potentiating
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TGF-β effects and inhibiting the renoprotective BMP7 signaling.
Furthermore it interacts with different growth factors and ECM
components, to modify their functions or turnovers (Lee et al.,
2015). But most of the signaling mechanisms of CTGF remain
unknown. Consistent with our results, Yokoi et al. (2004)
demonstrated increased CTGF levels in rats 7 days after UUO
and improved kidney fibrosis through antisense oligonucleotide
treatment. The reduction of CTGF protein levels is supposed
to be mediated through cGKI, as no effects were observed in
the cGKI-KO mice in our study. Nevertheless, data from TGF-
β stimulated rat renal cortical fibroblasts showed that RLX had
no influence on mRNA levels of CTGF (Masterson et al., 2004).
Kidney function was estimated through measurement of
serum creatinine levels using HPLC method. In accordance
with our results, Honma et al. (2014) also showed significantly
increased serum levels in mice 7 days after UUO. Through the
treatment of RLX a significant improvement of kidney function,
estimated by decreased serum creatinine levels, was observed in
our experiments as well as in previous experiments in RLX−/−
mice (Samuel et al., 2004) and a antiglomerular basement
membrane model (McDonald et al., 2003), when treated with
RLX. Whether this increase is due to increased renal plasma
flow and glomerular filtration rate (Danielson et al., 2006) of
the contralateral kidney or due to structural changes in the
obstructed kidney remains unclear.
CONCLUSION
Serelaxin signals via RXFP1 and the increase of NO/cGMP
and inhibits Smad- and ERK1-dependent TGF-β signaling
through cGKI. cGKI is additionally involved in PDE5a-
phosphorylation for the autoregulation of cGMP-dependent
effects. Our results identify RLX as antifibrotic agent and
broaden the understanding of its signaling process involving
cGMP/cGKI. Further elucidation of the RLX-signaling pathways
will be important for its possible applicability in the treatment of
CKDs.
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